Junjia Zhu

Junjia Zhu

Auto-generated profile, based on publicly available information

Junjia Zhu

Department of General Surgery, Jiangyin People’s Hospital, Nantong University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2016 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
JZJunJia Zhu
JunJia Zhu
YPYuwei Pu
Yuwei Pu
XYXiaoDong Yang
XiaoDong Yang
DZDeBao Zhang
DeBao Zhang
KZKui Zhao
Kui Zhao
CXchungen xing
chungen xing
Background. Parastomal hernia is a common complication after stoma formation, especially in permanent colostomy. The present meta-analysis aimed to evaluate the effectiveness of prophylactic mesh application during permanent colostomy for preventing parastomal hernia. Methods. Randomized controlled trials comparing outcomes in patients who underwent colostomy with or without prophylactic mesh application were identified from PubMed, EMBASE, Science Citation Index, and the Cochrane Libraries. Results. This meta-analysis included 8 randomized controlled trials with 522 participants. Our pooled results showed that prophylactic mesh application (mesh group) reduced the incidence of clinically detected parastomal hernia (risk ratio [RR]: 0.22; 95% confidence interval [CI]: 0.13–0.38; P<0.00001), radiologically detected parastomal hernia (RR: 0.62; 95% CI: 0.47–0.82; P=0.0008), and surgical repair for herniation (RR: 0.34; 95% CI: 0.14–0.83; P=0.02) when compared with conventional permanent colostomy formation (control group). The incidence of complications, including wound infection, peristomal infection, mesh infection, stomal necrosis and stenosis, stoma site pain, and fistula, was not higher in the mesh group than in the control group. Conclusions. Our meta-analysis demonstrated that prophylactic mesh application at the time of primary colostomy formation is a promising method for the prevention of parastomal herniation.

8 June 2022 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
JZJunjia Zhu
Junjia Zhu
WXWenlong Xu
Wenlong Xu
QSQi Sun
Qi Sun
JGJun Geng
Jun Geng
YYYifeng Yu
Yifeng Yu
ZZZhenguo Zhao
Zhenguo Zhao
Background. Postoperative ileus (POI) is an important complication after elective colorectal surgery, which prolongs hospital stay and increases hospital costs. Coffee has been reported to be beneficial for the recovery of gastrointestinal function. We aimed to investigate the effectiveness of coffee consumption in the treatment of POI, following elective colorectal surgery. Methods. A comprehensive literature search for medical subject heading (MeSH) terms, including coffee, caffeine, colon, rectum, and colorectal surgery was conducted in PubMed, Embase, and Cochrane Library until November 2021. A meta-analysis of postoperative outcomes was conducted to assess the effectiveness of coffee consumption on POI after colorectal surgery. Results. 726 articles were identified and six RCTs that captured 416 patients were included. The time to first defecation was reduced with postoperative coffee consumption compared to the control group ( h; 95% confidence interval: -17.79, -12.26; ). There was no difference in time to first flatus, time to tolerance for solid food, length of hospital stay, use of laxatives, reinsertion of nasogastric tube, need for reoperation, postoperative complications, and anastomotic leak between the groups. Coffee did not have any adverse effects. Conclusion. The current literature revealed that postoperative coffee consumption shortened the time to first defecation following elective colorectal surgery. Large sample and tightly controlled multicenter randomized clinical trials are needed to offer a more accurate evaluation of the efficacy of coffee.

6 June 2022 in International Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
JGJun Geng
Jun Geng
JWJing Wang
Jing Wang
YZYaowen Zhang
Yaowen Zhang
WSWenxiang Song
Wenxiang Song
JZJunjia Zhu
Junjia Zhu
ZWZhen Wu
Zhen Wu
Background and Aims. Regional anaesthesia reports to attenuate stress and inflammatory responses associated with surgical resection; however, the effectiveness of combined nerve blocks is less often investigated. We evaluated whether a combination of a pectoral nerve block (PNB) and stellate ganglion block (SGB) is more effective than a PNB alone in reducing these responses in women undergoing modified radical mastectomy (MRM). Methods. This is a prospective randomized controlled trial. Fifty patients with breast cancer were randomly allocated to receive an ultrasound-guided PNB ( , PNB only group) or ultrasound-guided PNB combined with SGB ( , combined blockade group). The primary outcome was perioperative plasma level of interleukin- (IL-) 6. Secondary outcomes included perioperative plasma levels of cortisol, glucose, IL-8, and tumour necrosis factor- (TNF-) α, pain scores, haemodynamic variables, sleep quality, and complications postsurgery. Results. The combined blockade group exhibited significantly lower IL-6 and TNF-α levels 24 h postsurgery. Cortisol levels were significantly lower in the combined blockade group at the end of the surgery. Glucose levels at the time of incision were lower in the combined blockade group. Pain scores up to 12 h postsurgery were significantly lower in the combined blockade group, which also exhibited better perioperative haemodynamic stability. Patients in the combined blockade group reported better sleep quality on the night of surgery. Conclusion. In patients undergoing MRM, PNB combined with SGB block effectively blunted perioperative inflammatory response than PNB alone. A combined block approach can also alleviate stress response and postoperative acute pain with stable perioperative haemodynamics and better postoperative sleep quality.

5 February 2023 in Journal of Investigative Surgery
Verified
Journal Article
Open access
JZJunjia Zhu
Junjia Zhu
QSQi Sun
Qi Sun
WXWenlong Xu
Wenlong Xu
JGJun Geng
Jun Geng
QFQiang Feng
Qiang Feng
SLSen Li
Sen Li
Surgical site infections (SSI) are common complications after surgery, which cause other complications and increase medical costs. However, the effect of negative-pressure wound therapy (NPWT) for ...

3 October 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
QSQi Sun
Qi Sun
ZGZhifu Gui
Zhifu Gui
ZZZhenguo Zhao
Zhenguo Zhao
WXWenlong Xu
Wenlong Xu
JZJunJia Zhu
JunJia Zhu
HHHao Hu
Hao Hu
Purpose. The purpose of this study was to explore the role of the lncRNA MNX1-AS1 and its related downstream signaling pathways in colorectal adenocarcinoma (COAD). Methods. COAD tissues and cells were prepared and treated with sh-MNX1-AS1, pcDNA-MNX1-AS1, sh-PPFIA4, LY29004, and their controls. CCK8 and colony formation assays were undertaken for evaluating cell proliferation. Tumor cell migratory ability was detected by transwell assay. Apoptosis detection was processed by YO-PRO-1/PI Staining. The regulated relationship between lncRNA MNX1-AS1 and PPFIA4 was confirmed by RIP-ChIP assay. Q-PCR was applied to detect genes related to tumor cell stemness, proliferation, migration, and apoptosis in each group. Finally, a xenograft tumor model was constructed to verify the result in vivo. Results. COAD patients with high expression of the lncRNA MNX1-AS1 have poor prognosis. LncRNA MNX1-AS1 promotes the stemness of COAD cells. PPFIA4 mediates lncRNA MNX1-AS1 expression and affects COAD cell stemness. LncRNA MNX1-AS1 accelerates proliferation and migration, while it suppresses apoptosis. LncRNA MNX1-AS1/PPFIA4 accelerates tumor growth in COAD model. LncRNA MNX1-AS1/PPFIA4 activates the downstream AKT/HIF-1α signaling pathway to promote COAD development. LY29004 significantly inhibits the tumorigenic ability of lncRNA MNX1-AS1 and PPFIA4. Conclusion. LncRNA MNX1-AS1/PPFIA4 activates AKT/HIF-1α signal pathway to promote the stemness of COAD cells, which could be a new target for COAD treatment.

1 October 2019 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
WLW. Liu
W. Liu
YXY. Xie
Y. Xie
LPL. Ping
L. Ping
MJM. Jiang
M. Jiang
GZG. Zhang
G. Zhang
YSY. Song
Y. Song
YF-H-2015005, a new type of CXCR4 antagonist, has demonstrated an ability to mobilize CD34+ cells in peripheral blood in pre-clinical studies. In this study, we evaluated the safety and efficacy of YF-H-2015005, as well as its pharmacokinetic (PK) and pharmacodynamic (PD) characteristics when administered with granulocyte colony-stimulating factor (G-CSF) in patients with non-Hodgkin lymphoma (NHL). This phase I, open-label, single arm study enrolled patients who had HNL, aged 18 to 65 years, and eligible for autologous stem cell transplantation. The stem cell mobilization regimen used was G-CSF (10 mg/kg/day subcutaneously) administration in the morning for up to 8 days, and YF-H-2015005 (0.24 mg/kg subcutaneously) initialed in the evening of the fourth day of G-CSF administration, and then continued for up to 4 days. Apheresis was initiated 9 to 10 hours after each evening dose of YF-H-2015005, and after the morning dose of G-CSF. Apheresis was repeated for up to 4 days or until ≥ 2 × 106 CD34+ cells/kg had been collected. A total of 15 patients (11 men and 4 women; median age 51 years, range 32-64 years) were enrolled in the study. Our PK data showed that YF-H-2015005 was rapidly absorbed after s.c. administration with a median Tmax of 0.5 hour, and then was rapidly cleared with a terminal half-life of 5.04 ± 1.00 hours. After the first dose of YF-H-2015005, a mean 2.0-fold to 2.9-fold increase in peripheral blood CD34+ cells from baseline was observed after 2 to 24 hours, with the maximum increase being observed at 10 hours after dosing. Fourteen (93%) patients reached the minimum target CD34+ cell collection of ≥ 2 × 106 cells/kg required for transplantation. No adverse event ≥ grade 3 or treatment-related serious adverse event occurred. YF-H-2015005 was safe and effective when used to mobilize CD34+ cells for transplantation in patients with NHL. CTR20170925. Hefei Yifan Biopharmaceuticals Inc. Hefei Yifan Biopharmaceuticals Inc. All authors have declared no conflicts of interest.